Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 19/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8044755 | 0.78 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL12027415 | 0.77 | MAPT (0.43) | CRHR1CYP3A4MAPTMAPK1 | |
| SCHEMBL7897727 | 0.77 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL6295020 | 0.76 | CRHR1 (0.42) | CRHR1CYP3A4MAPTMAPK1 | |
| SCHEMBL12046686 | 0.76 | CRHR1 (0.45) | CRHR1 | |
| SCHEMBL11365693 | 0.76 | PPIA (0.37) | CRHR1MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL11369618 | 0.75 | PPIA (0.36) | CRHR1MAPTMAPK1 | |
| SCHEMBL11363707 | 0.74 | GAA (0.40) | MAPT | |
| SCHEMBL9124554 | 0.73 | MEN1 (0.38) | CRHR1CYP3A4MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL11262372 | 0.73 | MAPT (0.40) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179919-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | EMORY UNIVERSITY (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179919-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | EMORY UNIVERSITY (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179919-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | EMORY UNIVERSITY (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130287687-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | UNIV EMORY (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130287687-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | UNIV EMORY (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130287687-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | UNIV EMORY (US) | 2013-10-31 | — | — | US | disclosed |
| US-8551996-B2 | Compounds, compositions, methods of synthesis, and methods of treatment | EMORY UNIVERSITY (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551996-B2 | Compounds, compositions, methods of synthesis, and methods of treatment | EMORY UNIVERSITY (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551996-B2 | Compounds, compositions, methods of synthesis, and methods of treatment | EMORY UNIVERSITY (US) | 2013-10-08 | — | — | US | disclosed |
| US-20110305636-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | EMORY UNIVERSITY (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2010096426-A2 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | EMORY UNIVERSITY (US) | 2010-08-26 | — | — | WO | disclosed |
| US-7125880-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-7067664-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-6956047-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050032846-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| US-6833378-B2 | Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders. | PFIZER INC | 2004-12-21 | — | — | US | disclosed |
| EP-1263732-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020016328-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001053263-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| US-6107301-A | PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179919-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | CRH, CRHR1, CRHR2 | CRHR1 2/4885CYP3A4 2207/4885MAPT 2625/4885 |
| US-20020016328-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | CRHR1 3/4885CYP3A4 2453/4885MAPT 2253/4885 |
| US-20110305636-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | CRH, CRHR1, CRHR2 | CRHR1 2/4885CYP3A4 2668/4885MAPT 2261/4885 |
| US-20050032846-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | CRHR1 3/4885CYP3A4 4070/4885MAPT 1457/4885 |
| US-20130287687-A1 | COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT | CRH, CRHR1, CRHR2 | CRHR1 2/4885CYP3A4 2207/4885MAPT 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.